NCT00070252View on ClinicalTrials.gov

Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

February 28, 2006

Study Completion Date

June 30, 2010

Conditions
Adult Solid NeoplasmInflammatory Breast CarcinomaMale Breast CarcinomaStage IIIA Breast CancerStage IIIB Breast Cancer
Interventions
DRUG

Capecitabine

Given PO

DRUG

Docetaxel

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Tipifarnib

Given orally (PO)

Trial Locations (7)

20060

Howard University Cancer Center CCOP, Washington D.C.

48201

Barbara Ann Karmanos Cancer Institute, Detroit

53201

University of Wisconsin Medical School, Milwaukee

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

85259

Mayo Clinic in Arizona, Scottsdale

32224-9980

Mayo Clinic in Florida, Jacksonville

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00070252 - Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer | Biotech Hunter | Biotech Hunter